We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

Raloxifene and Risk of Vertebral Fracture in Postmenopausal Women—Reply

Bruce Ettinger, MD
JAMA. 2000;283(17):2236-2237. doi:10.1001/jama.283.17.2235.
Text Size: A A A
Published online


In Reply: Patient allocation was performed using a randomization block design at each of the study sites. No individual involved with site contact or with data handling had access to treatment assignment prior to locking of the database. The quality assurance center responsible for judging the efficacy outcomes (from radiographs and bone density scans) had no access to treatment assignments.

In terms of the intent-to-treat analyses, the only other cause for discontinuation (besides an adverse event) that was different among treatment groups was early study completion due to excess bone loss or multiple fractures (4% of patients in the placebo group vs 1% in the raloxifene groups). While 23% of the women had discontinued the study medication by 36 months (25% of women in the placebo group and 22% of women assigned to raloxifene), follow-up radiographs were available for 89% of all women randomized. The 11% of patients who did not have a follow-up radiograph were equally distributed among treatment groups and had similar baseline characteristics such as number of prevalent fractures, bone mineral density, and bone marker levels; thus, it is very unlikely that those in the treatment and placebo groups had substantially different rates of fracture that could have altered the outcome. It is also extremely unlikely that all 11% experienced fractures, as Dr Halbekath and colleagues suggest.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.